Ohm,

Thanks , very interesting.

Please find below a link to a paper published by Drs. Lindner and Burger from Cleveland Clinic in regards to Pro-140: "PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice" . July 2017


https://www.bbmt.org/article/S1083-8791(17)30810-8/abstract

Quote:

---

We used this model to evaluate the role of a potent CCR5 inhibitor, PRO 140, on the role of immune cell engraftment in the pathogenesis of GVHD. PRO 140, a humanized monoclonal antibody to CCR5, was a robust inhibitor of acute GVHD in this model system as-measured by physical signs, weight loss, and survival curves

---

Quote:

---

The rationale for this approach is based on the role of CCR5, the G-linked protein receptor for CCL5 (aka RANTES), which is a potent chemokine involved in immune cell trafficking. Immune cell trafficking is believed to be crucial for the development of acute GVHD, which involves cutaneous and organ involvement including SPL, small intestine, and liver, with some involvement of BM and thymus.

---

Wanted to share some illustrative graphs as well but, unfortunately, have not figured out how to post figures in this board in spite of some serious efforts. So just gave up on that one.

The newer paper I believe will address some new results including histological evaluation of organ involvement and immune cell trafficking (something left out in this paper).

These are exiting times in the GvHD and Cytodyn.